O -phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 8139-8150

  Gooyit, Major ^a   Song, Wei ^a   Mahasenan, Kiran V ^a   Lichtenwalter, Katerina ^a   Suckow, Mark A ^a   Schroeder, Valerie A ^a   Wolter, William R ^a   Mobashery, Shahriar ^a   Chang, Mayland ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 3 [4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]UREA; 1 ISOPROPYL 3 [4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]UREA; 1 METHYL 3 [4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]UREA; 1 PROPYL 3 [4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]UREA; 4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYLETHYLCARBAMIC ACID; 4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYLISOPROPYLCARBAMIC ACID; 4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYLMETHYLCARBAMIC ACID; 4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYLPROPYLCARBAMIC ACID; ANTIMETASTATIC AGENT; CARBAMIC ACID DERIVATIVE; ETHYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBAMIC ACID; ETHYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBONIC ACID; GELATINASE A INHIBITOR; GELATINASE INHIBITOR; ISOPROPYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBAMIC ACID; ISOPROPYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBONIC ACID; METHYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBAMIC ACID; METHYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBONIC ACID; PROPYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBAMIC ACID; PROPYL[4 [4 [(THIIRAN 2 YLMETHYL)SULFONYL]PHENOXY]PHENYL]CARBONIC ACID; UNCLASSIFIED DRUG; UREA DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; ENZYME INHIBITION; FEMALE; LIVER MICROSOME METABOLISM; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; CARBAMATES; HETEROCYCLIC COMPOUNDS, 1-RING; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PHENOL; PHENYLUREA COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES;

EID: 84886547274     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401217d     Document Type: Article

References (32)

1. Fokas, E.; Steinbach, J. P.; Rodel, C. Biology of brain metastases and novel targeted therapies: time to translate the research Biochim. Biophys. Acta 2013, 1835, 61-75
2. Barnholtz-Sloan, J. S.; Sloan, A. E.; Davis, F. G.; Vigneau, F. D.; Lai, P.; Sawaya, R. E. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System J. Clin. Oncol. 2004, 22, 2865-2872
3. Xie, T. X.; Huang, F. J.; Aldape, K. D.; Kang, S. H.; Liu, M.; Gershenwald, J. E.; Xie, K.; Sawaya, R.; Huang, S. Activation of stat3 in human melanoma promotes brain metastasis Cancer Res. 2006, 66, 3188-3196
4. Preusser, M.; Capper, D.; Ilhan-Mutlu, A.; Berghoff, A. S.; Birner, P.; Bartsch, R.; Marosi, C.; Zielinski, C.; Mehta, M. P.; Winkler, F.; Wick, W.; von Deimling, A. Brain metastases: pathobiology and emerging targeted therapies Acta Neuropathol. 2012, 123, 205-222
5. Pardridge, W. M. Blood-brain barrier delivery Drug Discovery Today 2007, 12, 54-61
6. Deeken, J. F.; Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin. Cancer Res. 2007, 13, 1663-1674
7. Taskar, K. S.; Rudraraju, V.; Mittapalli, R. K.; Samala, R.; Thorsheim, H. R.; Lockman, J.; Gril, B.; Hua, E.; Palmieri, D.; Polli, J. W.; Castellino, S.; Rubin, S. D.; Lockman, P. R.; Steeg, P. S.; Smith, Q. R. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer Pharm. Res. 2012, 29, 770-781
8. Costa, D. B.; Kobayashi, S.; Pandya, S. S.; Yeo, W. L.; Shen, Z.; Tan, W.; Wilner, K. D. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J. Clin. Oncol. 2011, 29, e443-445
9. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development NeuroRx 2005, 2, 3-14
10. Page-McCaw, A.; Ewald, A. J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling Nature Rev. Mol. Cell Biol. 2007, 8, 221-233
11. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression Nature Rev. Cancer 2002, 2, 161-174
12. Devy, L.; Dransfield, D. T. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies Biochem. Res. Int. 2011, 2011, 191670
13. Overall, C. M.; Kleifeld, O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nature Rev. Cancer 2006, 6, 227-239
14. Talvensaari-Mattila, A.; Paakko, P.; Hoyhtya, M.; Blanco-Sequeiros, G.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma Cancer 1998, 83, 1153-1162
15. Still, K.; Robson, C. N.; Autzen, P.; Robinson, M. C.; Hamdy, F. C. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue Prostate 2000, 42, 18-25
16. Koshiba, T.; Hosotani, R.; Wada, M.; Miyamoto, Y.; Fujimoto, K.; Lee, J. U.; Doi, R.; Arii, S.; Imamura, M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma Cancer 1998, 82, 642-650
17. Nomura, H.; Fujimoto, N.; Seiki, M.; Mai, M.; Okada, Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas Int. J. Cancer 1996, 69, 9-16
18. Rojiani, M. V.; Alidina, J.; Esposito, N.; Rojiani, A. M. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma Int. J. Clin. Exp. Pathol. 2010, 3, 775-781
19. Brown, S.; Bernardo, M. M.; Li, Z. H.; Kotra, L. P.; Tanaka, Y.; Fridman, R.; Mobashery, S. Potent and selective mechanism-based inhibition of gelatinases J. Am. Chem. Soc. 2000, 122, 6799-6800
20. Forbes, C.; Shi, Q.; Fisher, J. F.; Lee, M.; Hesek, D.; Llarrull, L. I.; Toth, M.; Gossing, M.; Fridman, R.; Mobashery, S. Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases Chem. Biol. Drug Des. 2009, 74, 527-534
21. Lee, M.; Villegas-Estrada, A.; Celenza, G.; Boggess, B.; Toth, M.; Kreitinger, G.; Forbes, C.; Fridman, R.; Mobashery, S.; Chang, M. Metabolism of a highly selective gelatinase inhibitor generates active metabolite Chem. Biol. Drug Des. 2007, 70, 371-382
22. Gooyit, M.; Lee, M.; Schroeder, V. A.; Ikejiri, M.; Suckow, M. A.; Mobashery, S.; Chang, M. Selective water-soluble gelatinase inhibitor prodrugs J. Med. Chem. 2011, 54, 6676-6690
23. Bonfil, R. D.; Dong, Z.; Trindade Filho, J. C.; Sabbota, A.; Osenkowski, P.; Nabha, S.; Yamamoto, H.; Chinni, S. R.; Zhao, H.; Mobashery, S.; Vessella, R. L.; Fridman, R.; Cher, M. L. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth Am. J. Pathol. 2007, 170, 2100-2111
24. Lee, M.; Ikejiri, M.; Klimpel, D.; Toth, M.; Espahbodi, M.; Hesek, D.; Forbes, C.; Kumarasiri, M.; Noll, B. C.; Chang, M.; Mobashery, S. Structure-activity relationship for thiirane-based gelatinase inhibitors ACS Med. Chem. Lett. 2012, 3, 490-495
25. Minkkila, A.; Myllymaki, M. J.; Saario, S. M.; Castillo-Melendez, J. A.; Koskinen, A. M.; Fowler, C. J.; Leppanen, J.; Nevalainen, T. The synthesis and biological evaluation of para-substituted phenolic N -alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors Eur. J. Med. Chem. 2009, 44, 2994-3008
26. Mayer, P.; Brunel, P.; Chaplain, C.; Piedecoq, C.; Calmel, F.; Schambel, P.; Chopin, P.; Wurch, T.; Pauwels, P. J.; Marien, M.; Vidaluc, J. L.; Imbert, T. New substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity J. Med. Chem. 2000, 43, 3653-3664
27. Pochetti, G.; Montanari, R.; Gege, C.; Chevrier, C.; Taveras, A. G.; Mazza, F. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8) J. Med. Chem. 2009, 52, 1040-1049
28. Gooyit, M.; Lee, M.; Hesek, D.; Boggess, B.; Oliver, A. G.; Fridman, R.; Mobashery, S.; Chang, M. Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors Chem. Biol. Drug Des. 2009, 74, 535-546
29. Gooyit, M.; Suckow, M. A.; Schroeder, K. L.; Wolter, W. R.; Mobashery, S.; Chang, M. Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier ACS Chem. Neurosci. 2012, 3, 730-736
30. Ikejiri, M.; Bernardo, M. M.; Bonfil, R. D.; Toth, M.; Chang, M.; Fridman, R.; Mobashery, S. Potent mechanism-based inhibitors for matrix metalloproteinases J. Biol. Chem. 2005, 280, 33992-34002
31. Tao, P.; Fisher, J. F.; Shi, Q.; Mobashery, S.; Schlegel, H. B. Matrix metalloproteinase 2 (MMP2) inhibition: DFT and QM/MM studies of the deprotonation-initialized ring-opening reaction of the sulfoxide analogue of SB-3CT J. Phys. Chem. B 2009, 114, 1030-1037
32. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749